Kymera Q3 net loss $82.2M; KT-621 Phase 1b AD data due Dec 2025

Kymera Therapeutics, Inc.

2025-Q3 EPS reported -$2.71 revenue$36,341,000

Net loss $82.2M in Q3 2025 vs $62.5M in Q3 2024; R&D expenses rose to $74.1M.
Cash $978.7M as of Sept 30; runway into H2 2028 beyond multiple pipeline milestones.
KT-621 Phase 1b AD trial (BroADen) enrollment complete; top-line data expected Dec 2025.
KT-621 Phase 2b AD trial (BROADEN2) initiated; asthma Phase 2b (BREADTH) on track for 1Q26.
KT-579 (IRF5) IND-enabling studies completed; Phase 1 planned for early 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.